Literature DB >> 23821266

Amplification and sequencing of the hepatitis C virus NS3/4A protease and the NS5B polymerase regions for genotypic resistance detection of clinical isolates of subtypes 1a and 1b.

Diana Koletzki1, Theresa Pattery, Bart Fevery, Leen Vanhooren, Lieven J Stuyver.   

Abstract

Genotypic testing based on subtype-specific amplification and population Sanger sequencing for two nonstructural (NS) protein-coding regions, the NS3/4A protease and the NS5B polymerase, of the hepatitis C virus (HCV) genome is described here. The protocols include the molecular steps for RNA extraction, one-step RT-PCR followed by inner PCR and population Sanger sequencing, to obtain the sequence information of the target regions from the clinical isolates of HCV subtypes 1a and 1b, which can be used to detect any sequence change in the viral genome as for example caused by the development of drug resistance in these two common viral targets.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23821266     DOI: 10.1007/978-1-62703-484-5_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  4 in total

1.  In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.

Authors:  Thierry Verbinnen; Bart Fevery; Leen Vijgen; Tom Jacobs; Sandra De Meyer; Oliver Lenz
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

2.  Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin.

Authors:  John A Howe; Jianmin Long; Stuart Black; Robert Chase; Patricia McMonagle; Stephanie Curry; Seth Thompson; Mark J DiNubile; Anita Y M Howe
Journal:  Open Forum Infect Dis       Date:  2014-09-16       Impact factor: 3.835

3.  Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.

Authors:  Rong Liu; Stephanie Curry; Patricia McMonagle; Wendy W Yeh; Steven W Ludmerer; Patricia A Jumes; William L Marshall; Stephanie Kong; Paul Ingravallo; Stuart Black; Irene Pak; Mark J DiNubile; Anita Y M Howe
Journal:  Antimicrob Agents Chemother       Date:  2015-08-24       Impact factor: 5.938

4.  Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845.

Authors:  Leen Vijgen; Kim Thys; An Vandebosch; Pieter Van Remoortere; René Verloes; Sandra De Meyer
Journal:  Virol J       Date:  2017-05-31       Impact factor: 4.099

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.